← All trials
NCT05298306
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 17, 2022
- Primary completion
- Sep 30, 2022
- Completion date
- Nov 30, 2022
- First posted
- Mar 28, 2022
- Last posted
- Jul 28, 2022
- Enrollment
- 28
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Lateral Pharma Pty LtdLead sponsor
- University of AdelaideOverall official - principal investigator
- Southern Star Research Pty Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.